Study of the Efficacy and Safety of the Drug Ingaron (Interferon-gamma) in the Treatment of Anogenital Warts
The primary purpose of this study is to evaluate the effectiveness of destructive therapy for anogenital warts in combination with the use of Ingaron in comparison with destructive therapy.
Human Papillomavirus Infection|Anogenital Warts
DRUG: Interferon gamma human recombinant (IFN-G)
Recurrence of anogenital warts, Number of participants with recurrent anogenital warts, Day 11|Recurrence of anogenital warts, Number of participants with recurrent anogenital warts, Day 40|Recurrence of anogenital warts, Number of participants with recurrent anogenital warts, Day 100
Literature data and the results of preclinical studies of interferon-gamma, as well as the features of HPV immunopathogenesis, show the expediency of studying the use of Ingaron in this pathology.

The study was planned to include 50 outpatients of both sexes aged 18 to 50 years with a confirmed diagnosis of anogenital warts.

In the course of the study, Ingaron was administered at a dose of 100,000 IU once a day every other day in the period of 10 days.

Patients were divided into 2 groups: study and control.